This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Abbott (ABT) Gets FDA Approval for AVEIR DR Leadless Pacemaker
by Zacks Equity Research
Abbott (ABT) receives FDA approval for the AVEIR DR leadless pacemaker system, featuring the proprietary i2i technology.
New Strong Buy Stocks for July 6th
by Zacks Equity Research
GBX, GFF, AVDX, NCR and SIBN have been added to the Zacks Rank #1 (Strong Buy) List on July 6, 2023.
Syneos Health (SYNH) Announces a $7.1 Billion Merger Agreement
by Zacks Equity Research
Syneos Health (SYNH) is set to become private company following a $7.1 billion merger deal to be acquired by a private investment consortium.
Walgreens Boots (WBA) New Alliances Aid Growth, Cost Woe Stays
by Zacks Equity Research
Intensifying competition in the U.S. pharmacy retail drugstore market compels Walgreens Boots (WBA) to diversify its product offerings through new partnerships.
Penumbra (PEN) Hits 52-Week High: What's Driving the Rise?
by Zacks Equity Research
Penumbra (PEN) outperforms the industry and the S&P 500, backed by investors' optimism about the recently released first-quarter 2023 results.
Thermo Fisher (TMO) Partners With Pfizer to Expand NGS Testing
by Zacks Equity Research
Thermo Fisher's (TMO) latest collaboration with Pfizer is set to enhance localized access to NGS-based testing capabilities for breast and lung cancer across international markets.
Si-Bone (SIBN) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Si-Bone (SIBN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Si-Bone (SIBN) delivered earnings and revenue surprises of 21.95% and 12.03%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in TransMedics (TMDX): Can Its 12.3% Jump Turn into More Strength?
by Zacks Equity Research
TransMedics (TMDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Si-Bone (SIBN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Si-Bone (SIBN) delivered earnings and revenue surprises of 23.81% and 0.48%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Acadia (ACHC) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Acadia Healthcare's (ACHC) fourth-quarter results are likely to reflect an increase in patient days and admissions.
What's in Store for DENTSPLY SIRONA (XRAY) in Q4 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) fourth-quarter results are likely to reflect strong performance in the Technologies & Equipment business.
Universal Health (UHS) to Post Q4 Earnings: What to Expect
by Zacks Equity Research
Universal Health's (UHS) fourth-quarter results are likely to reflect an increase in same facility adjusted admissions in acute care hospitals.
Select Medical (SEM) to Post Q4 Earnings: What to Expect
by Zacks Equity Research
Select Medical's (SEM) fourth-quarter results are likely to reflect improved figures in the Rehabilitation Hospital business.
Avanos Medical (AVNS) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of 25% and 1.11%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Si-Bone (SIBN) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Si-Bone (SIBN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Teladoc's (TDOC) Q4 Earnings Beat on Growing Visits?
by Zacks Equity Research
The fourth-quarter results of Teladoc Health (TDOC) are likely to reflect a rise in visits and memberships.
Pediatrix Medical (MD) to Post Q4 Earnings: What to Expect
by Zacks Equity Research
Pediatrix Medical's (MD) fourth-quarter results are likely to reflect higher operating expenses and patient volume growth.
Si-Bone (SIBN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Si-Bone (SIBN) delivered earnings and revenue surprises of 8.89% and 0.29%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Si-Bone (SIBN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Si-Bone (SIBN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Does Si-Bone (SIBN) Have the Potential to Rally 42% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 41.6% in Si-Bone (SIBN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 50%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Si-Bone (SIBN) points to a 49.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Si-Bone (SIBN) delivered earnings and revenue surprises of -10.20% and 1.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Sight Sciences, Inc. (SGHT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Si-Bone (SIBN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Si-Bone (SIBN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.